Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Galina S Bogatkevich

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Current Rheumatology Reports|February 14, 2014
Recent advances in understanding the pathogenesis of scleroderma-interstitial lung diseaseTanjina Akter, Richard M Silver, Galina S Bogatkevich
Arthritis and Rheumatism|October 31, 2009
Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblastsGalina S Bogatkevich, Anna Ludwicka-Bradley, Richard M Silver
Seminars in Arthritis and Rheumatism|December 21, 2010
Coagulation and autoimmunity in scleroderma interstitial lung diseaseAnna Ludwicka-Bradley, Richard M Silver, Galina S Bogatkevich
Pulmonary Medicine|December 3, 2011
The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial EffectsGalina S Bogatkevich, Kristin B Highland, Tanjina Akter, et al.
International Journal of Molecular Sciences|May 25, 2024
IQGAP1 Regulates Actin Polymerization and Contributes to Bleomycin-Induced Lung FibrosisTanjina Akter, Ilia Atanelishvili, Richard M Silver, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 14, 2022
Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung FibrosisGalina S Bogatkevich, Ilia Atanelishvili, Andrew M Bogatkevich, et al.
Plos One|November 28, 2017
Establishment of an indirect ELISA for detection of the novel antifibrotic peptide M10Tanjina Akter, Ilia Atanelishvili, Atsushi Noguchi, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|August 5, 2008
Proteomic analysis of CTGF-activated lung fibroblasts: identification of IQGAP1 as a key player in lung fibroblast migrationGalina S Bogatkevich, Anna Ludwicka-Bradley, C Beth Singleton, et al.
Journal of Scleroderma and Related Disorders|February 27, 2025
Anti-fibrotic effects of thrombin inhibition in systemic sclerosis-associated interstitial lung disease: Proof of conceptGalina S Bogatkevich, Terrill J Huggins, Ahmed A Ismail, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|January 17, 2016
M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivoIlia Atanelishvili, Yuichiro Shirai, Tanjina Akter, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Current Rheumatology Reports|February 14, 2014
Recent advances in understanding the pathogenesis of scleroderma-interstitial lung diseaseTanjina Akter, Richard M Silver, Galina S Bogatkevich
Arthritis and Rheumatism|October 31, 2009
Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblastsGalina S Bogatkevich, Anna Ludwicka-Bradley, Richard M Silver
Seminars in Arthritis and Rheumatism|December 21, 2010
Coagulation and autoimmunity in scleroderma interstitial lung diseaseAnna Ludwicka-Bradley, Richard M Silver, Galina S Bogatkevich
Pulmonary Medicine|December 3, 2011
The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial EffectsGalina S Bogatkevich, Kristin B Highland, Tanjina Akter, et al.
International Journal of Molecular Sciences|May 25, 2024
IQGAP1 Regulates Actin Polymerization and Contributes to Bleomycin-Induced Lung FibrosisTanjina Akter, Ilia Atanelishvili, Richard M Silver, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 14, 2022
Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung FibrosisGalina S Bogatkevich, Ilia Atanelishvili, Andrew M Bogatkevich, et al.
Plos One|November 28, 2017
Establishment of an indirect ELISA for detection of the novel antifibrotic peptide M10Tanjina Akter, Ilia Atanelishvili, Atsushi Noguchi, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|August 5, 2008
Proteomic analysis of CTGF-activated lung fibroblasts: identification of IQGAP1 as a key player in lung fibroblast migrationGalina S Bogatkevich, Anna Ludwicka-Bradley, C Beth Singleton, et al.
Journal of Scleroderma and Related Disorders|February 27, 2025
Anti-fibrotic effects of thrombin inhibition in systemic sclerosis-associated interstitial lung disease: Proof of conceptGalina S Bogatkevich, Terrill J Huggins, Ahmed A Ismail, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|January 17, 2016
M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivoIlia Atanelishvili, Yuichiro Shirai, Tanjina Akter, et al.
Pageof 3